Orpha-Devel

Orpha-Devel was a specialized pharmaceutical company focused on the development and commercialization of orphan drugs for rare metabolic diseases. Founded in the early 1990s, the company played a pivotal role in bringing life-saving treatments to market for ultra-rare conditions, including hereditary tyrosinemia type 1 and homocystinuria. Its portfolio featured key products such as Orfadin (nitisinone) and Cystadane (betaine anhydrous), which addressed significant unmet medical needs in niche patient populations. Orpha-Devel was instrumental in navigating the early regulatory landscape for orphan medicinal products in Europe. The company was acquired by Orphan Europe in 2001, which subsequently became the rare disease business unit of the Recordati Group.